CEO Update - 13 November 2023

London Jefferies Week – the key global biotech week in London

It’s the Jefferies Healthcare Conference in London this week – which means a large proportion of the world’s top investors, life science CEOs and analysts are in town. I’m convinced this week has become a 'mini JPM week' – given the range of conferences and networking events that have mushroomed organically around the community we are privileged to host. Say it quietly but is this year the tipping point where London in November is a better value all-around than San Fran in January?

I look forward to having some form of this conversation every night this week – but especially at our joint event with BioCentury tomorrow – 'Planning for the biotech breakout 2023'.

Westminster whirl

Reshuffle today

Science Minister George Freeman MP – the man known to all of us as a staunch supporter and advocate for life sciences in Government and Parliament – has offered his resignation. He was the architect of the Coalition Government’s Strategy for UK Life Sciences back in 2011, which gave us the Biomedical Catalyst and Genomics England, and in 2014 he was appointed as the UK’s first-ever Minister for Life Sciences. Since has since held many roles in Government and always remained a close friend of the BIA and life sciences sector.




Victoria Atkins MP has been promoted to Secretary of Statement for Health and Social Care, replacing Steve Barclay MP. Vicky knows the BIA well as she was the Treasury Minister responsible for R&D tax reliefs when the Chancellor cut them last year. After two meetings with me, our Chair Dan Mahony, and our members, she saw the value of our sector and successfully worked with the Chancellor to deliver the enhanced rate for R&D-intensive companies at Spring Budget. The health department has also lost two junior ministers, Will Quince MP and Neil O'Brien MP, who have both chosen to leave government. These changes come at a critical time as the deadline for agreeing a new VPAS quickly approaches. I look forward to seeing Vicky and George’s replacement (yet to be announced) around the table at the Life Sciences Council next week.  

We will do a full write-up of what this means for our sector once the dust has settled and update our Guide to Government later in the week.

King's speech last week

This somewhat overshadows the King's Speech last week – which had a thin legislative gruel for our sector. The Data Protection and Digital Information Bill could be most interesting for us. According to a briefing from the Prime Minister’s Office, it will clarify the rules around using personal data for scientific research, ‘[maximising] post-Brexit freedoms to boost the economy and unleash innovation’. Our initial reading of the Bill is that it could allow researchers and innovators – including companies – to use health data for a wider range of research purposes than initially consented to, but we are still working with our member law firms to understand the scope of the text and how it will interact with common law. These reforms have been a long time coming – we fed into them with an industry-government roundtable late in November 2021, in which we called for better clarity for researchers – and complex, so we will be following them closely.

Continuing this theme, the King said: "The UK will continue to lead international discussions to ensure that Artificial Intelligence is developed safely’, referring to a legacy of the AI Safety Summit hosted at Bletchley Park earlier this month. Both these areas are key to our TechBio agenda. Our legal friends have also helped us look into the Bill published following the King's Speech to enable the UK’s entry into the Trans-Pacific Partnership, which is something I have personally been closely involved in working with the Government. There was concern that this could impact the UK’s intellectual property regime and our alignment with the European Patent Convention, but we secured special agreements with our future trading partners to avoid this.

The King’s Speech also mentioned proposals that will be brought forward to ‘increase the number [of young people] undertaking high-quality apprenticeships’. Life sciences presents great apprenticeship opportunities and our work with the Advanced Therapies Manufacturing Community serves as an exemplar for high-quality apprenticeships.  

Autumn Statement next Wednesday

The absence of a Pensions Bill following the Mansion House Reforms is noteworthy, however much of the necessary work doesn't require primary legislation. The upcoming week is set to be busy with the meeting of the Life Sciences Council and Autumn Statement (22 November), where the Chancellor is expected to provide a comprehensive update on the agenda. This moment is crucial as the Chancellor is poised to unveil plans for driving growth in the British economy, potentially including further developments in the Pensions agenda. Join our webinar on 24 November which will explain what this means for our sector.

Cancer Mission update

Last week I met with Professor Peter Johnson, Mission Chair for the UK Life Sciences Cancer Mission. It aims to make the UK a leading testbed for oncology innovation by accelerating the development and commercialisation of a new generation of cancer diagnostics and therapeutics, allowing patients to be diagnosed earlier and offered therapies specifically designed to target their cancer.

Since May 2023, Professor Johnson has designed, with the MRC, a funding call expanding the UK’s immunotherapy capabilities and generating insights into key questions like how to better target these treatments. This Cancer Immunotherapy Response Research Platform (CIRRP) funding call will award up to £9 million to a single consortium (involving industry partners) to develop a broad utility platform to improve our understanding of patient response, adverse effects and resistance to immunotherapies. Further details are on the website, and there is a webinar about the call on tomorrow  Tuesday 14 November.

For those with an interest in early cancer diagnostics, the mission is delivering a £12 million funding call, in collaboration with the NIHR i4i programme. The call, open until 12 December 2023, is funding clinical validation and evaluation of diagnostic innovations.

Through the Mission, Professor Johnson has also established a UK Cancer Research Strategy Forum, bringing together the UK’s major cancer research funders including all four nations of the UK and the third sector. This group will enable high-level strategic oversight of the UK’s cancer research landscape and close alignment of portfolio development by research groups and industry partners with delivery by the NHS research networks.

It was also brilliant to speak to Professor Johnson about his work with NHS England to establish the Cancer Vaccine Launchpad (CVLP). The CVLP aims to speed up the development of a promising new era of personalised cancer treatment. It will do this by providing a mechanism to refer cancer patients to participating partners’ cancer vaccine trials and by offering tumour molecular analysis and sequencing to identify eligible patients. NHSE hope that the CVLP will be able to refer patients to multiple partners’ cancer vaccine trials, expanding treatment options for patients enrolled on to the Launchpad and are keen to engage with cancer vaccine developers who may be interested in partnering. I’m sure this opportunity will be of great interest to a number of our members.

For further details about the cancer mission and its activities, please contact the Cancer Mission team.

BIA Future of UK Regulation Conference 2023 – final blog

We have produced a series of blogs reporting on the BIA conference, ‘The Future of UK Regulation: Driving Innovation in the Life Sciences’, which was a fantastic showcase of the BIA’s leading role in setting the regulatory agenda for innovative medicines. The latest blog looks at how the UK’s new international recognition route to market will work and compares and contrasts it with the national marketing authorisation procedure. Delegates at the conference heard directly from Julian Beach, MHRA, on the International Recognition Procedure (IRP), the implications for NICE from Dr Nick Crabb, and the perspectives from international regulators – Swissmedic and the US FDA. In this regard, the MHRA invited the BIA to attend a webinar on 29 November, which will provide the latest information about the new route, how to use the eligibility form and what to include in the eCTD submission. Members can register via this link.

Fantastic office opening – and do drop in to see us for a coffee in the new Victoria House lounge  


Thank you to the 200 folk who made our official office opening in Victoria House in Bloomsbury last Thursday such a great event. The buzz of the networking was fantastic and I hope seeing the building in action has inspired us all. As part of the opening, our friends Pioneer Group and Oxford Properties have fitted out a lounge next door to our offices for BIA members to use for drop-in meets in Central London until Christmas. It is a comfortable, spacious lounge with access to washrooms, wifi and a bar area where refreshments can be purchased (or please do pop into the BIA office for a free coffee!). BIA members can access the Victoria House lounge from this week onwards, to use as a base and to meet with colleagues between meetings. Please email Miriam Gedge for further details.

I look forward to seeing many of you around London this week!

Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

BugBiome wins discovery spark life science programme

BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures.

ValiRx seals deal to license late-stage cancer therapy

ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.

Arecor strikes co-development deal for specialty hospital product

Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.

Discovery Park Ventures expands fund to fuel UK Sci-Tech Startups

Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1million to £3 million, in order to capitalise on exciting investment opportunities and support its existing portfolio.

Vast West Midlands laboratory poised to propel UK life sciences

The Rosalind Franklin Laboratory, a state-of-the-art, fully fitted CL2 lab facility in Leamington Spa, Warwickshire, has come to market, with global real estate advisor, Avison Young, promoting it as an ‘unmissable opportunity’ for the UK life sciences sector.

Arecor continues collaboration with Lilly

Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™

Hartmut van Lengerich appointed as Chairman of Moa Technology

With over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13bn in worldwide sales

ACROBiosystems launches the world’s first GMP-grade DLL-4 Protein

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

Investors-in-residence join Cancer Research Horizons to advance Ventures team

Jonathan Tobin, a partner at life science venture capital firm Brandon Capital, and Genghis Lloyd-Harris, a senior advisor at life sciences investment firm, Abingworth, have joined Cancer Research Horizons’ Ventures team as advisory investors-in-residence.

More within